beta
Trial Radar AI
One study matched filter criteria
Card View
Back to Search

This Study is to Evaluate Whether Receiving Education and Glucose Monitoring With the CGM Device Will Improve Patient-reported Outcomes by Improving Patient's Satisfaction and Quality of Life (QOL) With Glucose Monitoring Device (CGM QOL) 37

Recruiting
Clinical Trial NCT06965803 (CGM QOL) is an observational study for Diabetes Mellitus that is recruiting. It started on October 1, 2025 with plans to enroll 37 participants. Led by Cedars-Sinai Medical Center, it is expected to complete by December 30, 2026. The latest data from ClinicalTrials.gov was last updated on March 18, 2026.
Brief Summary
The purpose of the study is to improve patient-reported outcomes by improving patient's satisfaction and quality of life (QOL) with glucose monitoring device through pre and post satisfaction survey of patient with diabetes.
Official Title

Continuous Glucose Monitor (CGM) Discharge Program

Conditions
Diabetes Mellitus
Other Study IDs
  • CGM QOL
  • STUDY00003936
NCT ID Number
NCT06965803
Start Date (Actual)
2025-10-01
Last Update Posted
2026-03-18
Completion Date (Estimated)
2026-12-30
Enrollment (Estimated)
37
Study Type
Observational
Status
Recruiting
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Patient Satisfaction (using a 5-point likert scale)
Glucose Monitoring Satisfaction Survey
15 days
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • aged 18 or older
  • diagnosed with Type 1 or Type 2 Diabetes who are on insulin
  • able to speak and understand English language
  • scheduled to receive a standard inpatient diabetes education consultation
  • must not have used CGM in the six months prior to admission
  • owns a smartphone
  • demonstrates the ability to follow instructions and be capable of providing informed consent to participate in the program

  • those who are known to be pregnant. This is due to complexity of pregnancy-related changes in glucose metabolism and increased skin sensitivity, or changes in skin condition to adhesives and materials used in CGM devices.
  • non-English speakers. As this is small study to evaluate which method is favorable using a survey only validated in English, enrolling non-English speakers would require additional resources/translations/personnel for evaluation and the education intervention that are not logistically possible right now.
Cedars-Sinai Medical Center logoCedars-Sinai Medical Center
Study Responsible Party
Matthew Monterola, Principal Investigator, Associate Director, Clinical Support Programs, Cedars-Sinai Medical Center
Study Central Contact
Contact: Mathew P Monterola, Doctor of Nursing Practice, 3109677434, [email protected]
1 Study Locations in 1 Countries

California

Cedars-Sina Medical Center, Los Angeles, California, 90048, United States
Recruiting